行情

NBSE

NBSE

NeuBase疗法
NASDAQ

实时行情|Nasdaq Last Sale

6.80
+0.22
+3.34%
休市 16:00 01/17 EST
开盘
6.64
昨收
6.58
最高
6.80
最低
6.50
成交量
11.62万
成交额
--
52周最高
8.30
52周最低
1.730
市值
1.16亿
市盈率(TTM)
-2.0865
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

NBSE 新闻

  • 外盘头条:一百多名亿万富翁即将齐聚达沃斯
  • 新浪美股.1小时前
  • LVMH股价去年大涨60% 实控人成最新福布斯富豪榜榜首
  • 新浪财经综合.2小时前
  • 英国央行行长称:全球经济正陷入“流动性陷阱”
  • 新浪美股.3小时前
  • 弹劾案审讯开始在即 民主党人、特朗普律师提交主张
  • 新浪财经.3小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

NBSE 简况

NeuBase Therapeutics, Inc., formerly Ohr Pharmaceutical, Inc. is a pharmaceutical company focused on the development of therapeutics and delivery technologies for the treatment of ocular disease. The Company's development pipeline consists of several programs and indications at various stages of development. Its product pipeline includes Squalamine Lactate Ophthalmic Solution 0.2% (Squalamine, also known as OHR-102), SKS Sustained Release Ocular Drug Delivery Platform Technology, Animal Model for Dry- Age-Related Macular Degeneration (AMD) and Non-Ophthalmology Assets. OHR-102 is a therapeutic product that provides a non-invasive therapy to improve vision outcomes. The SKS sustained release technology is designed to develop drug formulations for ocular disease. In the Company's animal model for dry-AMD, mice are immunized with a carboxyethylpyrrole, which is bound to mouse serum albumin.
展开

Webull提供Neubase Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。